Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
ZIVO Zivo Bioscience
2.680
-0.070-2.55%
Post Mkt Price
2.6800.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
0 0 0 0
Operating revenue
-- 0 -- 0 -- 0 -- 0
Cost of revenue
Gross profit
Operating expense
-2.72% 2M 18.19% 2.07M -2.74% 2.03M 5.56% 9.05M
Selling and administrative expenses
10.57% 1.4M 27.16% 1.63M -6.27% 1.35M 43.81% 6.93M
-General and administrative expense
10.57% 1.4M 27.16% 1.63M -6.27% 1.35M 43.81% 6.93M
Research and development costs
-23.89% 603.11K -6.38% 438.05K 5.11% 679.77K -43.55% 2.12M
Operating profit
2.72% -2M -18.19% -2.07M 2.74% -2.03M -5.81% -9.05M
Net non-operating interest income expense
-1,921.43% -4.25K 95.60% -4.24K 98.67% -1.81K 57.59% -233.28K
Non-operating interest expense
1,921.43% 4.25K -95.60% 4.24K -98.67% 1.81K -57.59% 233.28K
Other net income (expense)
122.52K
Special income (charges)
-- 0 -- -- -- -- -- 122.52K
-Less:Other special charges
-- -- -- -- -- -- -- -122.52K
Income before tax
-3.61% -2M -12.26% -2.07M 8.59% -2.03M -0.63% -9.16M
Income tax
Net income
-3.61% -2M -12.26% -2.07M 8.59% -2.03M -0.63% -9.16M
Net income continuous Operations
-3.61% -2M -12.26% -2.07M 8.59% -2.03M -0.63% -9.16M
Minority interest income
Net income attributable to the parent company
-3.61% -2M -12.26% -2.07M 8.59% -2.03M -0.63% -9.16M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-3.61% -2M -12.26% -2.07M 8.59% -2.03M -0.63% -9.16M
Basic earnings per share
0.00% -0.21 21.43% -0.22 72.50% -0.22 25.00% -1.2
Diluted earnings per share
0.00% -0.21 21.43% -0.22 72.50% -0.22 25.00% -1.2
Dividend per share
Currency Unit
USDUSDUSDUSD
Audit Opinions
------Unqualified Opinion with Explanation

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Zivo Bioscience, Inc. engages in the study, development, and commercialization of natural nutritional compounds and bioactive molecules. It offers proprietary algae strain, extracts and supernatants, and bioactive compounds. The company was founded by Howard R. Baer on March 28, 1983 and is headquartered in Keego Harbor, MI.
CEO: Mr. John B. Payne
Market: NASDAQ
Listing Date: 05/28/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist